Laboratory of Chromatin and Gene Regulation During Development, INSERM UMR1163, Imagine Institute, Paris, France.
Paris Descartes, Sorbonne Paris Cité University, Imagine Institute, Paris, France.
Stem Cells Transl Med. 2017 Dec;6(12):2106-2114. doi: 10.1002/sctm.17-0192. Epub 2017 Oct 28.
Hematopoiesis is the process of blood cell formation starting from hematopoietic stem/progenitor cells (HSPCs). The understanding of regulatory networks involved in hematopoiesis and their impact on gene expression is crucial to decipher the molecular mechanisms that control hematopoietic development in physiological and pathological conditions, and to develop novel therapeutic strategies. An increasing number of epigenetic studies aim at defining, on a genome-wide scale, the cis-regulatory sequences (e.g., promoters and enhancers) used by human HSPCs and their lineage-restricted progeny at different stages of development. In parallel, human genetic studies allowed the discovery of genetic variants mapping to cis-regulatory elements and associated with hematological phenotypes and diseases. Here, we summarize recent epigenetic and genetic studies in hematopoietic cells that give insights into human hematopoiesis and provide a knowledge basis for the development of novel therapeutic approaches. As an example, we discuss the therapeutic approaches targeting cis-regulatory regions to reactivate fetal hemoglobin for the treatment of β-hemoglobinopathies. Epigenetic studies allowed the definition of cis-regulatory sequences used by human hematopoietic cells. Promoters and enhancers are targeted by transcription factors and are characterized by specific histone modifications. Genetic variants mapping to cis-regulatory elements are often associated with hematological phenotypes and diseases. In some cases, these variants can alter the binding of transcription factors, thus changing the expression of the target genes. Targeting cis-regulatory sequences represents a promising therapeutic approach for many hematological diseases. Stem Cells Translational Medicine 2017;6:2106-2114.
造血是血细胞从造血干细胞/祖细胞(HSPCs)形成的过程。了解造血过程中涉及的调控网络及其对基因表达的影响,对于解析控制生理和病理条件下造血发育的分子机制,以及开发新的治疗策略至关重要。越来越多的表观遗传研究旨在在全基因组范围内定义人类 HSPCs 及其在不同发育阶段的谱系受限后代使用的顺式调控序列(例如启动子和增强子)。与此同时,人类遗传研究发现了映射到顺式调控元件的遗传变异体,并与血液表型和疾病相关。在这里,我们总结了造血细胞中最近的表观遗传和遗传研究,这些研究深入了解了人类造血,并为开发新的治疗方法提供了知识基础。例如,我们讨论了靶向顺式调控区域以重新激活胎儿血红蛋白用于治疗β-血红蛋白病的治疗方法。表观遗传研究定义了人类造血细胞使用的顺式调控序列。启动子和增强子受转录因子的靶向作用,并具有特定的组蛋白修饰。映射到顺式调控元件的遗传变异体通常与血液表型和疾病相关。在某些情况下,这些变体可以改变转录因子的结合,从而改变靶基因的表达。靶向顺式调控序列是许多血液疾病有前途的治疗方法。《干细胞转化医学》2017;6:2106-2114.